US2008103179A1PendingUtilityA1
Combination Therapy

Individually held — no corporate assignee on recordPriority: Oct 27, 2006Filed: Jun 15, 2007Published: May 1, 2008
Est. expiryOct 27, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 3/10A61P 43/00A61P 9/12A61K 31/137A61K 31/35A61K 31/423A61P 25/00A61P 25/08A61P 25/32A61K 31/135A61K 31/435A61K 45/06A61P 3/04A61K 31/133
PatentIndex Score
Cited by
References
Claims
Abstract

The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea compound (e.g. zonisamide).
Claims

exact text as granted — not AI-modified
1 . A method of treating epilepsy comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         2 . The method of  claim 1 , wherein the antiepileptic agent is a sulfamate compound, or a sulfonylurea compound. 
     
     
         3 . The method of  claim 2 , wherein the sulfamate compound is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         4 . The method of  claim 2 , wherein the sulfonylurea is zonisamide. 
     
     
         5 . The method of  claim 1 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         6 . The method of  claim 3 , wherein the topiramate is administered at between about 15 mg and about 1500 mg per day. 
     
     
         7 . The method of  claim 5 , wherein the sympathomimetic agent is phentermine. 
     
     
         8 . The method of  claim 7 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         9 . A method of treating diabetes comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         10 . The method of  claim 9 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         11 . The method of  claim 10 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(l-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(i-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(l-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(l-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         12 . The method of  claim 10 , wherein the sulfonylurea is zonisamide. 
     
     
         13 . The method of  claim 9 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         14 . The method of  claim 11 , wherein the topiramate is administered at between about 15 mg and about 1500 mg per day. 
     
     
         15 . The method of  claim 13 , wherein the sympathomimetic agent is phentermine. 
     
     
         16 . The method of  claim 15 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         17 . A method of treating hypertension or pulmonary hypertension comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         18 . The method of  claim 17 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         19 . The method of  claim 18 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         20 . The method of  claim 17 , wherein the sulfonylurea is zonisamide. 
     
     
         21 . The method of  claim 17 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         22 . The method of  claim 19 , wherein the topiramate is administered at between about 15 mg and about 1500 mg per day. 
     
     
         23 . The method of  claim 21 , wherein the sympathomimetic agent is phentermine. 
     
     
         24 . The method of  claim 23 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         25 . A method of treating migraine comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         26 . The method of  claim 25 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         27 . The method of  claim 26 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D)-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(l-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         28 . The method of  claim 25 , wherein the sulfonylurea is zonisamide. 
     
     
         29 . The method of  claim 25 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         30 . The method of  claim 27 , wherein the topiramate is administered at between about 20 mg and about 1500 mg per day. 
     
     
         31 . The method of  claim 29 , wherein the sympathomimetic agent is phentermine. 
     
     
         32 . The method of  claim 31 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         33 . A method of treating alcohol addiction comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         34 . The method of  claim 33 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         35 . The method of  claim 34 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(l-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D)-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(l-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl-]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         36 . The method of  claim 34 , wherein the sulfonylurea is zonisamide. 
     
     
         37 . The method of  claim 33 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         38 . The method of  claim 35 , wherein the topiramate is administered at between about 20 mg and about 1500 mg per day. 
     
     
         39 . The method of  claim 37 , wherein the sympathomimetic agent is phentermine. 
     
     
         40 . The method of  claim 39 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         41 . A method of treating an impulse control disorder comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         42 . The method of  claim 41 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         43 . The method of  claim 42 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate. 
     
     
         44 . The method of  claim 42 , wherein the sulfonylurea is zonisamide. 
     
     
         45 . The method of  claim 41 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         46 . The method of  claim 43 , wherein the topiramate is administered at between about 15 mg and about 1500 mg per day. 
     
     
         47 . The method of  claim 45 , wherein the sympathomimetic agent is phentermine. 
     
     
         48 . The method of  claim 47 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         49 . A method of treating sleep apnea comprising administering to a subject in need thereof an antiepileptic agent and a sympathomimetic agent. 
     
     
         50 . The method of  claim 49 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         51 . The method of  claim 50 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(l-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4, 5 -O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         52 . The method of  claim 50 , wherein the sulfonylurea is zonisamide. 
     
     
         53 . The method of  claim 49 , wherein the sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol., phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         54 . The method of  claim 51 , wherein the topiramate is administered at between about 15 mg and about 1500 mg per day. 
     
     
         55 . The method of  claim 53 , wherein the sympathomimetic agent is phentermine. 
     
     
         56 . The method of  claim 55 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         57 . A pharmaceutical composition comprising an antiepileptic agent and bupropion. 
     
     
         58 . The composition of  claim 41 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         59 . The composition of  claim 42 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4, 5 -O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(1-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         60 . The composition of  claim 41 , wherein the sulfonylurea is zonisamide. 
     
     
         61 . The composition of  claim 43 , wherein the composition comprises between about 15 mg and about 1500 mg of topiramate. 
     
     
         62 . A kit, comprising a therapeutically effective dose of an antiepileptic agent and bupropion, wherein the antiepileptic agent and the bupropion are in separate and discrete dosage forms, and instructions for its use. 
     
     
         63 . The kit of  claim 46 , wherein the antiepileptic agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         64 . The kit of  claim 47 , wherein the sulfamate is selected from topiramate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-L-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose methylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose butylsulfamate; 2,3-O-(l-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose ethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose octylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose 2-propenylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose phenylmethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclopropylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose cyclobutylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose (2,2,2-trifluoroethyl)sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose dimethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose diethylsulfamate; 2,3-O-(1-methylethylidene)-4,5-O-sulfonyl-beta-D-fructopyranose azido sulfamate; (S)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; (R)-2,3-O-(1-methylethylidene)-4,5-O-sulfinyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-ethylpropylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; 2,3-O-(1-methylethylidene)-4,5-O-[N -(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(l-methylethylidene)-4,5-O-[N-(4-methylbenzenesulfonyl)imidosulfonyl]-beta-D-fructopyranose sulfamate; 2,3-O-(cyclohexylidene)-4,5-O-sulfonyl-beta-D-fructopyranose sulfamate; and (S)-4,5-O-[N-(1,1-dimethylethoxycarbonyl)imidosulfinyl]-2,3-O-(l-methylethy lidene)-beta-D-fructopyranose sulfamate. 
     
     
         65 . The kit of  claim 47 , wherein the sulfonylurea is zonisamide. 
     
     
         66 . The kit of  claim 46 , wherein the composition comprises between about 20 mg and about 1500 mg of topiramate. 
     
     
         67 . A method of ameliorating at least one side effect in a subject treated with a composition which possesses anorectic, sedative or central nervous system depressant properties by administering a therapeutically effective amount or a sub-therapeutic effective amount of a sympathomimetic agent such that at least one sedation or CNS side effect of said composition is inhibited or reduced. 
     
     
         68 . The method of  claim 67 , wherein said composition is a centrally active agent, canabinoid antagonist or 5HT2C-selective serotonin receptor agonist. 
     
     
         69 . The method of  claim 68 , wherein said centrally active agent is a sulfamate compound or a sulfonylurea compound. 
     
     
         70 . The method of  claim 68 , wherein said canabinoid antagonist is rimonabant, MK-0364 or MK-0493. 
     
     
         71 . The method of  claim 68 , wherein said 5HT2C-selective serotonin receptor agonist is locaserin HCl. 
     
     
         72 . The method of  claim 67 , wherein said sympathomimetic agent is selected from bupropion, phenylethylamine, epinephrine, norepinephrine, epinine, dopamine, dobutamine, nordefrin, ethylnorepinephrine, isoproterenol, protokylol, isoetharine, metaproterenol, terbutaline, metaraminol, phenylephrine, tyramine, hydroxyamphetamine, methoxyphenamine, methoxamine, albuterol, amphetamine, methamphetamine, benzphetamine, ephedrine, phenylpropanolamine, mephentermine, phentermine, chlorphentermine, fenfluramine, propylhexedrine and diethylpropion. 
     
     
         73 . The method of  claim 72 , wherein the sympathomimetic agent is phentermine. 
     
     
         74 . The method of  claim 73 , wherein the phentermine is administered at between about 2 mg and about 60 mg per day. 
     
     
         75 . A method of reducing at least one of the central nervous system side effects associated with monotherapeutic administration of a composition which possesses anorectic, sedative or central nervous system depressant properties in a subject so treated, the method comprising administering a combination of a sympathomimetic agent and said composition which possesses anorectic, sedative or central nervous system depressant properties, whereby the dose of the composition which possesses anorectic, sedative or central nervous system depressant properties in the combination is lower than that of the dose of the composition which possesses anorectic, sedative or central nervous system depressant properties in the monotherapy, wherein the monotherapy and the combination therapy produce similar therapeutic results. 
     
     
         76 . A method of expanding the therapeutic window of a composition possessing anorectic, sedative, or central nervous system depressant properties, by administering a sympathomimetic agent in combination with said composition possessing anorectic, sedative, or central nervous system depressant properties.
Join the waitlist — get patent alerts

Track US2008103179A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.